These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

522 related items for PubMed ID: 15363566

  • 1. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 2. Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies.
    Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N.
    BJU Int; 2005 Sep; 96(4):572-7. PubMed ID: 16104912
    [Abstract] [Full Text] [Related]

  • 3. Long-term therapy with the dual 5alpha-reductase inhibitor dutasteride is well tolerated in men with symptomatic benign prostatic hyperplasia.
    Schulman C, Pommerville P, Höfner K, Wachs B.
    BJU Int; 2006 Jan; 97(1):73-9; discussion 79-80. PubMed ID: 16336332
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.
    Na Y, Ye Z, Zhang S, Chinese Dutasteride Phase III Trial (ARIA108898) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):29-39. PubMed ID: 22017520
    [Abstract] [Full Text] [Related]

  • 5. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Becher E, Miñana B, Mirone V, Castro R, Wilson T, Montorsi F, CombAT Study Group.
    Eur Urol; 2009 Feb 01; 55(2):461-71. PubMed ID: 19013011
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
    Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET.
    Urology; 2004 Apr 01; 63(4):709-15. PubMed ID: 15072886
    [Abstract] [Full Text] [Related]

  • 7. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement.
    Gittelman M, Ramsdell J, Young J, McNicholas T.
    J Urol; 2006 Sep 01; 176(3):1045-50; discussion 1050. PubMed ID: 16890688
    [Abstract] [Full Text] [Related]

  • 8. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
    Musquera M, Fleshner NE, Finelli A, Zlotta AR.
    Expert Rev Anticancer Ther; 2008 Jul 01; 8(7):1073-9. PubMed ID: 18588452
    [Abstract] [Full Text] [Related]

  • 9. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
    Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.
    BJU Int; 2011 Aug 01; 108(3):388-94. PubMed ID: 21631695
    [Abstract] [Full Text] [Related]

  • 10. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS.
    Urology; 2004 Sep 01; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [Abstract] [Full Text] [Related]

  • 11. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan 01; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP.
    BJU Int; 2011 Mar 01; 107(6):946-54. PubMed ID: 21332630
    [Abstract] [Full Text] [Related]

  • 13. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA.
    Prostate; 2009 Nov 01; 69(15):1624-34. PubMed ID: 19588525
    [Abstract] [Full Text] [Related]

  • 14. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR.
    Ann Pharmacother; 2006 Apr 01; 40(4):658-65. PubMed ID: 16569804
    [Abstract] [Full Text] [Related]

  • 15. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 01; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 16. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.
    Urology; 2011 Sep 01; 78(3):641-6. PubMed ID: 21764428
    [Abstract] [Full Text] [Related]

  • 17. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F, CombAT Study Group.
    Eur Urol; 2010 Jan 01; 57(1):123-31. PubMed ID: 19825505
    [Abstract] [Full Text] [Related]

  • 18. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS, Roehrborn CG, Wolford E, Wilson TH.
    J Urol; 2007 Apr 01; 177(4):1408-13. PubMed ID: 17382742
    [Abstract] [Full Text] [Related]

  • 19. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Brown CT, Nuttall MC.
    Int J Clin Pract; 2003 Oct 01; 57(8):705-9. PubMed ID: 14627182
    [Abstract] [Full Text] [Related]

  • 20. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R, Ray P, Major-Walker K, Shannon J, Rittmaster R.
    Prostate Cancer Prostatic Dis; 2007 Oct 01; 10(2):149-54. PubMed ID: 17189955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.